BPS804
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Jun 1, 2011 → Dec 1, 2012
NCT ID
NCT01417091About BPS804
BPS804 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is completed. This product is registered under clinical trial identifier NCT01417091. Target conditions include Osteogenesis Imperfecta.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216486 | Phase 2 | Withdrawn |
| NCT01417091 | Phase 2 | Completed |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 85 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 3 | 77 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 76 |
| Romosozumab | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 76 |
| Fresolimumab | Sanofi | Phase 1 | 32 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 32 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 60 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |